Summary & Overview
CPT 51720: Bladder Instillation of Anticarcinogenic Agent
CPT code 51720 represents the bladder instillation of an anticarcinogenic agent, a procedure integral to the management of bladder cancer and related urological conditions. This code is widely used in outpatient settings, reflecting its importance in ongoing cancer care and disease management. Nationally, the procedure is covered by major payers including Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare, ensuring broad access for patients across diverse insurance plans.
This publication provides a comprehensive overview of CPT 51720, including clinical context, payer coverage, and relevant policy updates. Readers will gain insight into the procedure's role in urology, typical sites of service, and its relationship to other bladder-related CPT codes. The summary also highlights common billing modifiers and associated provider taxonomies, offering clarity for stakeholders navigating reimbursement and compliance. Benchmarks and trends in utilization are discussed, equipping healthcare professionals, administrators, and policy analysts with the information needed to understand the national landscape for bladder instillation procedures.
CPT Code Overview
CPT 51720 describes the bladder instillation of an anticarcinogenic agent, including retention time. This procedure is commonly performed in the field of urology and is typically provided in an outpatient setting, such as a physician's office. The instillation is used as part of treatment protocols for patients with bladder conditions requiring targeted therapy with anticarcinogenic agents.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an individual diagnosed with bladder cancer or other bladder-related conditions who requires treatment with an anticarcinogenic agent. The procedure is performed in an outpatient setting, such as a urology office. The workflow includes the patient presenting with symptoms or a diagnosis (e.g., hematuria, bladder-neck obstruction, acute cystitis), followed by the urologist instilling an anticarcinogenic agent into the bladder via catheterization. The agent is retained for a specified period to maximize therapeutic effect. This procedure is commonly performed by urology specialists and may be part of ongoing management for bladder neoplasms or other relevant conditions.
Coding Specifications
-
Modifiers:
- Modifier
26: Used to indicate the professional component of the service, typically when the physician provides only the interpretation and reporting. - Modifier
TC: Used for the technical component, indicating the use of equipment, supplies, and technical staff. - Modifier
59: Used to denote a distinct procedural service, when the procedure is separate from other services performed on the same day.
- Modifier
-
Provider Taxonomies:
| Taxonomy Code |
|---|